Pluristem Therapeutics Inc. (PSTI) |
1 -0.03 (-2.91%) 07-26 00:00 |
Open: | 1.02 |
High: | 1.0401 |
Low: | 0.9595 |
Volume: | 170,627 |
Market Cap: | 41(M) |
PE Ratio: | -0.68 |
Exchange: | NASDAQ Global Market |
Industry: | Biotechnology |
Sector: | Healthcare |
Technical analysis | ||||
sell | buy |
Resistance 2: | 1.21 |
Resistance 1: | 1.04 |
Pivot price: | 1.00 |
Support 1: | 0.99 |
Support 2: | 0.96 |
52w High: | |
52w Low: |
Pluristem Therapeutics Inc. operates as a bio-technology company. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trial for the recovery after surgery for hip fracture; in Phase II clinical trail for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18, which has completed Phase I clinical trial incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of acute radiation syndrome. The company has a license agreement for conducting clinical trials of PLX-PAD product in South Korea. It also has a collaborative project nTRACK, that examines gold nano particles labeling of stem cells; and has collaboration agreement with the NASA's Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions. Pluristem Therapeutics Inc. was incorporated in 2001 and is based in Haifa, Israel.
EPS | -46050000.000 |
Book Value | 0.000 |
PEG Ratio | 0.00 |
Gross Profit | 0.000 |
Profit Margin (%) | 0.00 |
Operating Margin (%) | -20.00 |
Return on Assets (ttm) | 212.8 |
Return on Equity (ttm) | -37.3 |
Wed, 13 Mar 2024
Pluristem Therapeutics Shares March Higher, Can It Continue? - Yahoo Lifestyle Australia
Sun, 10 Mar 2024
Pluristem Completes Enrollment in Phase I Hematology Study - Yahoo Lifestyle Australia
Mon, 25 Jul 2022
Pluristem Therapeutics renames as Pluri - Seeking Alpha
Mon, 25 Jul 2022
Pluristem Therapeutics Inc. Changes its Name to “Pluri Inc.” Reflecting the Company's Strategy to Leverage its ... - GlobeNewswire
Tue, 08 Mar 2022
Pluristem and Tnuva Appoint Food Tech Veteran Eyal Rosenthal as Chief Executive Officer of their New Joint Venture - BioSpace
Tue, 18 Jan 2022
Biotechnology Company Pluristem, and Israel's Largest Food Producer Tnuva, Launch Landmark Collaboration to ... - PR Newswire
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |